Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis

The trouble with quality filtering based on relative Cramér-Rao lower bounds

(2015) Roland Kreis   MAGNETIC RESONANCE IN MEDICINE

Clinical Relevance of Brain Volume Measures in Multiple Sclerosis

(2014) Nicola De Stefano et al.   CNS DRUGS

Brain atrophy in natalizumab-treated patients: A 3-year follow-up

(2014) J Sastre-Garriga et al.   Multiple Sclerosis Journal

Magnetic Resonance Spectroscopy Markers of Disease Progression in Multiple Sclerosis

(2014) Sara Llufriu et al.   JAMA Neurology

Preventing brain atrophy should be the gold standard of effective therapy in MS (after the first year of treatment): Yes

(2013) Richard A Rudick et al.   Multiple Sclerosis Journal

Preventing brain atrophy should be the gold standard of effective theraphy in MS (after the first year of treatment): No

(2013) M Filippi et al.   Multiple Sclerosis Journal

Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes

(2013) Angela Vidal-Jordana et al.   Multiple Sclerosis Journal

Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis: a prospective, 
non-randomized pilot study

(2012) E. Portaccio et al.   EUROPEAN JOURNAL OF NEUROLOGY

The relationship between inflammatory activity and brain atrophy in natalizumab treated patients

(2012) M. Magraner et al.   EUROPEAN JOURNAL OF RADIOLOGY

Procedure for quantitative1H magnetic resonance spectroscopy and tissue characterization of human brain tissue based on the use of quantitative magnetic resonance imaging

(2012) A. Tisell et al.   MAGNETIC RESONANCE IN MEDICINE

CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis

(2012) Jeppe Romme Christensen et al.   Multiple Sclerosis Journal

CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome

(2012) M Khalil et al.   Multiple Sclerosis Journal

Neurofilaments as biomarkers in multiple sclerosis

(2012) Charlotte E Teunissen et al.   Multiple Sclerosis Journal

Association between Change in Normal Appearing White Matter Metabolites and Intrathecal Inflammation in Natalizumab-Treated Multiple Sclerosis

(2012) Johan Mellergård et al.   PLoS One

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

(2010) Martin Gunnarsson et al.   ANNALS OF NEUROLOGY

Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis

(2010) Ranjan Dutta et al.   PROGRESS IN NEUROBIOLOGY

Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid

(2009) J. Mellergård et al.   Multiple Sclerosis Journal

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

(2008) R. Zivadinov et al.   NEUROLOGY